To make an appointment, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment online
As a leader in cancer research, Karmanos is able to offer patients access to innovative treatments and clinical trials that are often times not available anywhere else.
To offer hope and longer life to patients with all types of cancer, Karmanos offers the latest types of therapy through our clinical trials program. Through clinical trials, we are creating new knowledge about how therapies fight cancer and provide national leadership in testing these new therapies.
We understand that cancer is a complex disease that demands complex care. We provide each patient with a dynamic, carefully constructed treatment plan focused on their specific cancer and their unique needs.
We listen to you to design a plan that provides you with respect, compassionate care and is responsive to your emotional and practical concerns.
The Barbara Ann Karmanos Cancer Institute and Wayne State University present the annual Breast Cancer Symposium 2025 on Saturday, April 12, from 8 a.m. to 3 p.m. at the Detroit Marriott Troy (200 W. Big Beaver Road, Troy, Michigan). This year’s keynote speakers include Sara Hurvitz, M.D., FACP, professor of Medicine, Smith Family Endowed Chair in Women’s Health, head of the Division of Hematology and Oncology, and senior vice president of the Clinical Research Division at the University of Washington Sc...
Patient Power Ovarian suppression is a treatment that stops estrogen from being produced in a woman’s ovaries. Jailan Elayoubi, M.D. , medical oncologist and member of the Breast Cancer Multidisciplinary Team at Karmanos, explained what type of breast cancer patients this treatment is usually given to and to whom the treatment is not offered. Read the article here .
A Barbara Ann Karmanos Cancer Institute clinical researcher and her team have received $16,000 to further research in precision medicine for breast cancer treatment. Common Citizen leadership delivered the check to Jailan Elayoubi, M.D. , medical oncologist and member of the Breast Cancer and Phase 1 Clinical Trials Multidisciplinary Teams, in November 2023. Dr. Elayoubi and her team have made significant strides in studying biomarkers and tumor molecular characteristics that may predict sensitivity and...